These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 24210498)

  • 1. Ligand-targeted liposome design: challenges and fundamental considerations.
    Noble GT; Stefanick JF; Ashley JD; Kiziltepe T; Bilgicer B
    Trends Biotechnol; 2014 Jan; 32(1):32-45. PubMed ID: 24210498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PEGylated liposomal doxorubicin targeted to α5β1-expressing MDA-MB-231 breast cancer cells.
    Shroff K; Kokkoli E
    Langmuir; 2012 Mar; 28(10):4729-36. PubMed ID: 22268611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design of liposomal formulations for cell targeting.
    Nogueira E; Gomes AC; Preto A; Cavaco-Paulo A
    Colloids Surf B Biointerfaces; 2015 Dec; 136():514-26. PubMed ID: 26454541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterogeneous liposome membranes with pH-triggered permeability enhance the in vitro antitumor activity of folate-receptor targeted liposomal doxorubicin.
    Mamasheva E; O'Donnell C; Bandekar A; Sofou S
    Mol Pharm; 2011 Dec; 8(6):2224-32. PubMed ID: 21899300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice.
    Gabizon A; Horowitz AT; Goren D; Tzemach D; Shmeeda H; Zalipsky S
    Clin Cancer Res; 2003 Dec; 9(17):6551-9. PubMed ID: 14695160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Towards clinical translation of ligand-functionalized liposomes in targeted cancer therapy: Challenges and opportunities.
    Belfiore L; Saunders DN; Ranson M; Thurecht KJ; Storm G; Vine KL
    J Control Release; 2018 May; 277():1-13. PubMed ID: 29501721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liposomal drug delivery systems: from concept to clinical applications.
    Allen TM; Cullis PR
    Adv Drug Deliv Rev; 2013 Jan; 65(1):36-48. PubMed ID: 23036225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liposomal nanomedicines in the treatment of prostate cancer.
    Kroon J; Metselaar JM; Storm G; van der Pluijm G
    Cancer Treat Rev; 2014 May; 40(4):578-84. PubMed ID: 24216226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Her2-targeted pegylated liposomal doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passage.
    Shmeeda H; Tzemach D; Mak L; Gabizon A
    J Control Release; 2009 Jun; 136(2):155-60. PubMed ID: 19331844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineered peptides for the development of actively tumor targeted liposomal carriers of doxorubicin.
    Shahin M; Soudy R; El-Sikhry H; Seubert JM; Kaur K; Lavasanifar A
    Cancer Lett; 2013 Jul; 334(2):284-92. PubMed ID: 23073474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin.
    Li X; Ding L; Xu Y; Wang Y; Ping Q
    Int J Pharm; 2009 May; 373(1-2):116-23. PubMed ID: 19429296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced anticancer efficacy by ATP-mediated liposomal drug delivery.
    Mo R; Jiang T; Gu Z
    Angew Chem Int Ed Engl; 2014 Jun; 53(23):5815-20. PubMed ID: 24764317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PR_b-targeted PEGylated liposomes for prostate cancer therapy.
    Demirgöz D; Garg A; Kokkoli E
    Langmuir; 2008 Dec; 24(23):13518-24. PubMed ID: 18954096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liposomal drug formulations in the treatment of rheumatoid arthritis.
    van den Hoven JM; Van Tomme SR; Metselaar JM; Nuijen B; Beijnen JH; Storm G
    Mol Pharm; 2011 Aug; 8(4):1002-15. PubMed ID: 21634436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biotechnological approaches toward nanoparticle biofunctionalization.
    Avvakumova S; Colombo M; Tortora P; Prosperi D
    Trends Biotechnol; 2014 Jan; 32(1):11-20. PubMed ID: 24182737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma.
    Loi M; Marchiò S; Becherini P; Di Paolo D; Soster M; Curnis F; Brignole C; Pagnan G; Perri P; Caffa I; Longhi R; Nico B; Bussolino F; Gambini C; Ribatti D; Cilli M; Arap W; Pasqualini R; Allen TM; Corti A; Ponzoni M; Pastorino F
    J Control Release; 2010 Jul; 145(1):66-73. PubMed ID: 20346382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stealth liposomes: an improved sustained release system for 1-beta-D-arabinofuranosylcytosine.
    Allen TM; Mehra T; Hansen C; Chin YC
    Cancer Res; 1992 May; 52(9):2431-9. PubMed ID: 1568213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status.
    van der Meel R; Vehmeijer LJ; Kok RJ; Storm G; van Gaal EV
    Adv Drug Deliv Rev; 2013 Oct; 65(10):1284-98. PubMed ID: 24018362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surface-active liposomes for targeted cancer therapy.
    Sofou S
    Nanomedicine (Lond); 2007 Oct; 2(5):711-24. PubMed ID: 17976032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Streptokinase loading in liposomes for vascular targeted nanomedicine applications: encapsulation efficiency and effects of processing.
    Holt B; Gupta AS
    J Biomater Appl; 2012 Jan; 26(5):509-27. PubMed ID: 20659961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.